ClinicalTrials.gg
CompletedNCT02722044Updated May 16, 2018Results posted

Usability of an AI for M923 in Subjects With Moderate to Severe RA

A Phase 3 interventional study of M923 and Autoinjector in Rheumatoid Arthritis, sponsored by Momenta Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-16.

Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
76th of 87
33 · median 160
Started
2016
with 4 others
Phase 3
36 of 87
1 open now
Registered
73rd of 87
by date

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 76th largest by enrollment, is one of 5 that started in 2016, is one of 36 in phase 3, and was the 73rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants ≥18 years old at the time of Screening
  2. Able to understand and communicate with the Investigator and comply with the requirements of the study, and must give a written, signed and dated before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations.
  3. RA diagnosed for at least 6 months before Screening
  4. Meets classification criteria for rheumatoid arthritis (RA) by 2010 American College of Rheumatology/European League Against Rheumatism criteria
  5. Active disease at Screening and Baseline
  6. Participants must have at least 1 documented swollen and/or tender joint in their hand or wrist of the dominant hand as assessed by the Investigator or designated assessor
  7. Must be willing and able to attempt self-administration of subcutaneous (SC) injection(s)
  8. Male participants and their female partners must be willing to comply with the restrictions for this study from the time of the first administration of product (IP) until 3 months after the last dose.
  9. Female participants must have a negative pregnancy test at screening and on admission to the clinic, and must not be lactating and must be using an acceptable method of contraception throughout the study and for 3 months after the last dose, or be of non-. Non-pregnant female partners of male participants who are of childbearing potential should use an effective form of contraception.

Exclusion criteria

Exclusion Criteria:

  1. Prior use of systemic tumor necrosis factor (TNF) inhibitor therapy.
  2. Prior use of rituximab
  3. Prior use of abatacept, tocilizumab and tofacitinib within 4 weeks prior to Screening
  4. Current use of a conventional disease modifying anti-rheumatic drugs (DMARD) other than the following: methotrexate orally (≤25 mg/day), hydroxychloroquine (≤400 mg/day) or sulfasalazine (≤3 g/day)) at a stable dose for at least 4 weeks prior to Screening. If discontinued, methotrexate, hydroxychloroquine, and sulfasalazine must have been discontinued at least 4 weeks prior to Baseline. No other conventional DMARDs are permitted and no combination therapy is permitted.
  5. Prior use of cytotoxic or alkylating agents or must have been discontinued for at least 90 days prior to Baseline
  6. Current use of oral at a dose >10 mg/day prednisone or equivalent or change of dose within 2 weeks prior to Screening
  7. Current use of more than 1 nonsteroidal anti-inflammatory drug.
  8. Prior use of injectable corticosteroids (intramuscular [IM], intra-articular [IA], or intravenous [IV]) within 6 weeks prior to Baseline
  9. Prior or current use of other self-injected drugs, eg, insulin
  10. All other prior non-RA concomitant treatments must be on a stable dose for at least 4 weeks before Baseline
  11. Meets Class IV Steinbrocker criteria for disability/activities of daily living
  12. Laboratory abnormalities at Screening deemed by the Investigator and/or Sponsor.
  13. Presence of fibromyalgia, another rheumatologic illness or inflammatory arthritis, eg, systemic lupus erythematosus, gout. The presence of secondary Sjogren's syndrome is permitted.
  14. Joint surgery within the last 8 weeks prior to Screening
  15. Severe, progressive, or uncontrolled renal, hepatic, metabolic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac or neurologic disease, including pleural effusions or ascites, which in the opinion of the Investigator would preclude the participant from adhering to or completing the study or where participation in the study exposes the participant to unfavorable benefit/risk
  16. History or presence of signs and/or symptoms or a diagnosis of a demyelinating disorder
  17. History or presence of Class III or IV congestive heart failure
  18. History or presence of symptoms suggestive of lymphoproliferative disorders, lymphoma, leukemia, myeloproliferative disorders, or multiple myeloma
  19. Existing or history of any malignancy except adequately treated or excised non- basal cell or squamous cell cancer of the skin or cervical carcinoma in situ, with no more than 3 lifetime basal cell or squamous cell carcinomas
  20. Chronic infections, recurrent infections (3 or more of the same infection requiring anti-infective treatment in any rolling 12-month period); any recent infection (ie, in the last 30 days) requiring hospitalization or any infection requiring parenteral anti-infective therapy within 30 days or oral infective therapies within 14 days of Baseline; herpes zoster within 6 months of Baseline or more than 2 lifetime episodes of herpes zoster; or history of systemic fungal infection or opportunistic infection (eg, coccidioidomycosis, histoplasmosis, toxoplasmosis)
  21. History or presence of (HIV), or C virus
  22. History of active tuberculosis (TB) or untreated or inadequately treated latent TB.
  23. Participant has been exposed to an product (IP) within 30 days (or 5 half-lives) prior to enrollment, whichever is longer, or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  24. Participant is a family member or employee of the Investigator or Baxalta or its partners
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    All Study Participants

    All study participants to receive M923 administered via a subcutaneous auto-injector (AI)

    Biological: M923 · Device: Autoinjector

Interventions

  • BiologicalM923

    Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

    Also known as: Adalimumab

  • DeviceAutoinjector

    Subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Usability of the Auto-injector (AI) at Week 4

    The primary usability measure was the participant rating captured in the PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules at Week 4. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

    Time frame: Week 4

Secondary outcomes

  1. Number of Participants With Successful Injections as Assessed by the Observer at Week 4

    Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

    Time frame: Week 4

  2. Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 4

    Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

    Time frame: Week 4

  3. Usability of the Auto-injector at Baseline

    The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Baseline. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

    Time frame: Baseline (Day 1)

  4. Usability of the Auto-injector at Week 2

    The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Week 2. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

    Time frame: Week 2

  5. Number of Participants With Successful Injections as Assessed by the Observer at Baseline

    Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

    Time frame: Baseline (Day 1)

  6. Number of Participants With Hazard-free Injections as Assessed by the Observer at Baseline

    Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

    Time frame: Baseline (Day 1)

  7. Number of Participants With Successful Injections as Assessed by the Observer at Week 2

    Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

    Time frame: Week 2

  8. Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 2

    Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

    Time frame: Week 2

  9. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

    Hematology, clinical chemistry, and urinalysis clinical laboratory parameters were assessed. The hematology panel consisted of complete blood count, hemoglobin, hematocrit, mean cell volume, total leukocytes, and platelet counts. The clinical chemistry panel consisted of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, lactate dehydrogenase, creatine kinase, C-reactive protein, cholesterol, triglycerides, total protein, sodium, potassium, chloride, blood urea nitrogen, creatinine, albumin, calcium, phosphate, glucose, glycosylated hemoglobin, uric acid, and bicarbonate. The urinalysis panel consisted of leucocytes, protein, bilirubin, urobilinogen, glucose, ketones, blood pH, nitrite, and specific gravity. Clinical significance was assessed by the Investigator.

    Time frame: Baseline; 32 Weeks

  10. Number of Participants With Vital Signs Outside the Expected Range

    Vital signs included respiratory rate, body temperature, pulse rate, and systolic and diastolic blood pressure.

    Time frame: 32 Weeks

  11. Number of Participants With Clinically Significant Changes in Twelve-lead Electrocardiogram (ECG) Findings

    Clinical significance was assessed by the Investigator.

    Time frame: Baseline; 32 Weeks

  12. Number of Participants With Adverse Events Leading to Premature Study Withdrawal

    The number of participants who had an adverse event that led to premature study withdrawal was assessed.

    Time frame: 32 Weeks

  13. Number of Participants With Treatment-emergent Injection Site Reactions

    An injection site reaction is defined as pain, tenderness, erythema/redness, induration/swelling, and other. If an injection site reaction was observed, a physician was to characterize and document the reaction as an adverse event (AE). Treatment-emergent adverse events (TEAEs) are defined as AEs that started or worsened in severity on or after the first dose of study medication, until study completion/withdrawal or within 30 days following the last treatment for early withdrawn participants.

    Time frame: 32 Weeks

  14. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of Anti-drug Antibodies (ADAs) at Baseline

    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Baseline (Day 1)

  15. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 4

    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Week 4

  16. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 12

    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Week 12

  17. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 24

    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Week 24

  18. Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at the Safety Follow-Up Visit

    A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Safety Follow-Up Visit (32 Weeks)

  19. Immunogenicity of M923 Assessed as the Number of Participants With Neutralizing Anti-drug Antibodies (nADAs) at Baseline

    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Baseline (Day 1)

  20. Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 4

    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Week 4

  21. Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 12

    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Week 12

  22. Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 24

    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Week 24

  23. Immunogenicity of M923 Assessed as the Number of Participants With nADAs at the Safety Follow-Up Visit

    A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

    Time frame: Safety Follow-Up Visit (32 Weeks)

07

Results

Posted May 1, 2018

Participant flow

A total of 51 participants were screened, and 33 participants were enrolled in the study.

Participant flow — Overall Study
MilestoneM923 40 mg
Started33
Completed28
Not completed5
Withdrew: Adverse event2
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1
Withdrew: Did not meet criteria at week 141

Outcome measures

PrimaryUsability of the Auto-injector (AI) at Week 4

The primary usability measure was the participant rating captured in the PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules at Week 4. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

Time frame:
Week 4
Reported as:
Mean · Scores on a scale
Usability of the Auto-injector (AI) at Week 4
Scores on a scaleM923 40 mg
Feelings about injections: PRE8.15 ± 2.049
Feelings about injections: POST8.17 ± 1.930
Self-image: POST9.27 ± 2.061
Self-confidence: PRE8.12 ± 2.183
Self-confidence: POST8.39 ± 2.287
Pain/skin reactions during/after injection: POST9.33 ± 0.630
Pain during/after injection: POST8.76 ± 1.234
Skin reactions: POST9.90 ± 0.301
Ease of use of the AI: POST8.72 ± 2.072
Satisfaction with self-injection: PRE8.39 ± 1.887
Satisfaction with self-injection: POST8.89 ± 1.369
SecondaryNumber of Participants With Successful Injections as Assessed by the Observer at Week 4

Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With Successful Injections as Assessed by the Observer at Week 4
ParticipantsM923 40 mg
Successfully completed P7, P10, and P1131
Successfully completed all 14 instructions31
SecondaryNumber of Participants With Hazard-free Injections as Assessed by the Observer at Week 4

Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 4
ParticipantsM923 40 mg
Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 431
SecondaryUsability of the Auto-injector at Baseline

The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Baseline. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

Time frame:
Baseline (Day 1)
Reported as:
Mean · Scores on a scale
Usability of the Auto-injector at Baseline
Scores on a scaleM923 40 mg
Feelings about injections: PRE7.20 ± 2.810
Feelings about injections: Post7.98 ± 2.507
Self-image: POST9.52 ± 1.357
Self-confidence: PRE6.34 ± 3.218
Self-confidence: POST7.96 ± 2.535
Pain/skin reactions: POST8.99 ± 0.865
Pain during/after injection: POST8.15 ± 1.591
Skin reaction: POST9.84 ± 0.326
Ease of use of the AI: POST8.26 ± 1.956
Satisfaction with AI: PRE7.98 ± 2.365
Satisfaction with AI: POST8.57 ± 1.490
SecondaryUsability of the Auto-injector at Week 2

The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Week 2. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Usability of the Auto-injector at Week 2
Scores on a scaleM923 40 mg
Feelings about injections: PRE7.82 ± 2.294
Feelings about injections: POST8.06 ± 2.057
Self-image: POST9.60 ± 1.307
Self-confidence: PRE7.77 ± 2.311
Self-confidence: POST8.09 ± 2.319
Pain/skin reactions: POST9.22 ± 0.747
Pain during/after injection: POST8.55 ± 1.490
Skin reactions: POST9.89 ± 0.213
Ease of use of the AI: POST8.49 ± 2.098
Satisfaction with AI: PRE8.39 ± 1.773
Satisfaction with AI: POST8.65 ± 1.448
SecondaryNumber of Participants With Successful Injections as Assessed by the Observer at Baseline

Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

Time frame:
Baseline (Day 1)
Reported as:
Count of participants · Participants
Number of Participants With Successful Injections as Assessed by the Observer at Baseline
ParticipantsM923 40 mg
Successfully completed P7, P10, and P1131
Successfully completed all 14 instructions31
SecondaryNumber of Participants With Hazard-free Injections as Assessed by the Observer at Baseline

Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

Time frame:
Baseline (Day 1)
Reported as:
Count of participants · Participants
Number of Participants With Hazard-free Injections as Assessed by the Observer at Baseline
ParticipantsM923 40 mg
Number of Participants With Hazard-free Injections as Assessed by the Observer at Baseline31
SecondaryNumber of Participants With Successful Injections as Assessed by the Observer at Week 2

Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."

Time frame:
Week 2
Reported as:
Count of participants · Participants
Number of Participants With Successful Injections as Assessed by the Observer at Week 2
ParticipantsM923 40 mg
Successfully completed P7, P10, and P1131
Successfully completed all 14 instructions31
SecondaryNumber of Participants With Hazard-free Injections as Assessed by the Observer at Week 2

Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.

Time frame:
Week 2
Reported as:
Count of participants · Participants
Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 2
ParticipantsM923 40 mg
Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 231
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

Hematology, clinical chemistry, and urinalysis clinical laboratory parameters were assessed. The hematology panel consisted of complete blood count, hemoglobin, hematocrit, mean cell volume, total leukocytes, and platelet counts. The clinical chemistry panel consisted of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, lactate dehydrogenase, creatine kinase, C-reactive protein, cholesterol, triglycerides, total protein, sodium, potassium, chloride, blood urea nitrogen, creatinine, albumin, calcium, phosphate, glucose, glycosylated hemoglobin, uric acid, and bicarbonate. The urinalysis panel consisted of leucocytes, protein, bilirubin, urobilinogen, glucose, ketones, blood pH, nitrite, and specific gravity. Clinical significance was assessed by the Investigator.

Time frame:
Baseline; 32 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
ParticipantsM923 40 mg
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments0
SecondaryNumber of Participants With Vital Signs Outside the Expected Range

Vital signs included respiratory rate, body temperature, pulse rate, and systolic and diastolic blood pressure.

Time frame:
32 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Outside the Expected Range
ParticipantsM923 40 mg
Number of Participants With Vital Signs Outside the Expected Range13
SecondaryNumber of Participants With Clinically Significant Changes in Twelve-lead Electrocardiogram (ECG) Findings

Clinical significance was assessed by the Investigator.

Time frame:
Baseline; 32 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Twelve-lead Electrocardiogram (ECG) Findings
ParticipantsM923 40 mg
Number of Participants With Clinically Significant Changes in Twelve-lead Electrocardiogram (ECG) Findings0
SecondaryNumber of Participants With Adverse Events Leading to Premature Study Withdrawal

The number of participants who had an adverse event that led to premature study withdrawal was assessed.

Time frame:
32 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Premature Study Withdrawal
ParticipantsM923 40 mg
Number of Participants With Adverse Events Leading to Premature Study Withdrawal2
SecondaryNumber of Participants With Treatment-emergent Injection Site Reactions

An injection site reaction is defined as pain, tenderness, erythema/redness, induration/swelling, and other. If an injection site reaction was observed, a physician was to characterize and document the reaction as an adverse event (AE). Treatment-emergent adverse events (TEAEs) are defined as AEs that started or worsened in severity on or after the first dose of study medication, until study completion/withdrawal or within 30 days following the last treatment for early withdrawn participants.

Time frame:
32 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Injection Site Reactions
ParticipantsM923 40 mg
Number of Participants With Treatment-emergent Injection Site Reactions1
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of Anti-drug Antibodies (ADAs) at Baseline

A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Baseline (Day 1)
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of Anti-drug Antibodies (ADAs) at Baseline
ParticipantsM923 40 mg
Overall ADA/negative predose6
Overall ADA/positive predose27
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 4

A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 4
ParticipantsM923 40 mg
Overall ADA/negative6
Overall ADA/positive26
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 12

A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 12
ParticipantsM923 40 mg
Overall ADA/negative5
Overall ADA/positive18
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 24

A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 24
ParticipantsM923 40 mg
Overall ADA/negative5
Overall ADA/positive17
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at the Safety Follow-Up Visit

A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Safety Follow-Up Visit (32 Weeks)
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at the Safety Follow-Up Visit
ParticipantsM923 40 mg
Overall ADA/negative6
Overall ADA/positive25
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With Neutralizing Anti-drug Antibodies (nADAs) at Baseline

A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Baseline (Day 1)
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With Neutralizing Anti-drug Antibodies (nADAs) at Baseline
ParticipantsM923 40 mg
Overall nADA/negative26
Overall nADA/positive7
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 4

A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 4
ParticipantsM923 40 mg
Overall nADA/negative26
Overall nADA/positive6
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 12

A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 12
ParticipantsM923 40 mg
Overall nADA/negative17
Overall nADA/positive6
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 24

A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 24
ParticipantsM923 40 mg
Overall nADA/negative18
Overall nADA/positive4
SecondaryImmunogenicity of M923 Assessed as the Number of Participants With nADAs at the Safety Follow-Up Visit

A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.

Time frame:
Safety Follow-Up Visit (32 Weeks)
Reported as:
Count of participants · Participants
Immunogenicity of M923 Assessed as the Number of Participants With nADAs at the Safety Follow-Up Visit
ParticipantsM923 40 mg
Overall nADA/negative24
Overall nADA/positive7

Adverse events

Collected over From the date of Screening until the Safety Follow-Up Visit (approximately 32 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
M923 40 mg0/33 (0%)2/33 (6.1%)31/33 (93.9%)
Most frequent serious events
Most frequent serious events
EventM923 40 mg
Duodenal ulcer perforationGastrointestinal disorders1/33
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/33
SyncopeNervous system disorders1/33
Most frequent other events
Most frequent other events
EventM923 40 mg
Injection site painGeneral disorders27/33
Injection site erythemaGeneral disorders10/33
Injection site bruisingGeneral disorders5/33
Injection site swellingGeneral disorders5/33
Injection site coldnessGeneral disorders4/33
Injection site pruritusGeneral disorders4/33
Administrative site painGeneral disorders2/33
Injection site indurationGeneral disorders2/33
NasopharyngitisInfections and infestations2/33
Musculoskeletal painMusculoskeletal and connective tissue disorders2/33

Baseline characteristics

Safety Analysis Set: all participants who received study medication

Age, Continuous
Age, Continuous(years)M923 40 mg
Mean58.2 ± 9.82
Sex: Female, Male
Sex: Female, Male(Participants)M923 40 mg
Female28
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)M923 40 mg
Hispanic or Latino7
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)M923 40 mg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White29
More than one race0
Unknown or Not Reported0
08

Study locations

7 sites
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Medication Management, LLC
    Greensboro, North Carolina 27408, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Altoona Center for Clinical Research, PC
    Duncansville, Pennsylvania 16635, United States
  • Austin Regional Clinic, PA
    Austin, Texas 78731, United States
  • Accurate Clinical Management
    Houston, Texas 77004, United States
  • Accurate Clinical Research, Inc.
    Houston, Texas 77034, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

Results were first posted in May 2018, 1 year 2 months after primary completion. A results delay was requested in Feb 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2016
First posted
Mar 29, 2016
Start
Apr 2016
Primary completionActual
Feb 21, 2017
CompletionActual
Feb 21, 2017
Results delay requested
Feb 14, 2018
Results first posted
May 1, 2018
Last update
May 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02722044
Responsible party
Sponsor
First posted
Mar 29, 2016
Start date
Apr 2016
Primary completion
Feb 21, 2017
Completion
Feb 21, 2017
Results posted
May 1, 2018
Last update
May 16, 2018

Study contacts

John Caminis, MD
study director · Baxalta US Inc., now part of Shire

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion